Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Abstract Introduction New oral anticoagulants (NOACs) are approved for use in nonvalvular
atrial fibrillation (AF). Objectives This study aimed to evaluate the efficacy and safety of …

Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

Purpose: There is uncertainty as to which anticoagulant should be used in non-valvular
atrial fibrillation (AF) with valvular heart disease. This systematic review and meta-analysis …

Pivotal trials comparing direct oral anticoagulants (DOACs) against warfarin in patients with
atrial fibrillation (AF) predominantly involved patients with high stroke risk. This study aimed …

Abstract Purpose of Review To review the clinical evidence underlying the efficacy and
safety of the use of direct oral anticoagulants (DOACs) for the treatment of patients with …

Background There are no clear consensus guidelines on the indications and types of
anticoagulation therapies in patients with bio-prosthetic valves either with concomitant atrial …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin
among Asians with non-valvular atrial fibrillation (NVAF) remains unclear in the real-world …

Objective: To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for
non–Food and Drug Administration approved indications. Data Sources: Articles from …

Direct oral anticoagulants (DOACs) are indicated by the European Medicines Agency and
US Food and Drug Administration for stroke prevention in patients with nonvalvular atrial …